Collegium Pharmaceutical (NASDAQ:COLL) Sets New 52-Week Low – What’s Next?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price reached a new 52-week low on Tuesday . The stock traded as low as $28.30 and last traded at $28.30, with a volume of 534 shares changing hands. The stock had previously closed at $28.62.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on COLL. Piper Sandler reissued a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

Collegium Pharmaceutical Price Performance

The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a 50 day moving average price of $30.61 and a 200 day moving average price of $34.05. The firm has a market cap of $1.08 billion, a PE ratio of 14.37 and a beta of 0.82.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in COLL. GAMMA Investing LLC grew its holdings in Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 792 shares during the period. CWM LLC boosted its position in shares of Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares in the last quarter. Virtus Fund Advisers LLC acquired a new stake in shares of Collegium Pharmaceutical in the third quarter valued at about $72,000. Finally, AXA S.A. purchased a new stake in Collegium Pharmaceutical during the second quarter worth about $209,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.